Bank of New York Mellon Corp Has $5.14 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Bank of New York Mellon Corp increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 8.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 124,328 shares of the company’s stock after acquiring an additional 9,629 shares during the quarter. Bank of New York Mellon Corp owned about 0.26% of Mirum Pharmaceuticals worth $5,141,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Frazier Life Sciences Management L.P. lifted its stake in Mirum Pharmaceuticals by 1.2% in the third quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock valued at $256,245,000 after buying an additional 75,000 shares during the period. State Street Corp lifted its stake in Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after buying an additional 297,511 shares during the period. Geode Capital Management LLC lifted its stake in Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after buying an additional 29,017 shares during the period. Lord Abbett & CO. LLC acquired a new position in Mirum Pharmaceuticals in the third quarter valued at about $28,913,000. Finally, Loomis Sayles & Co. L P acquired a new position in Mirum Pharmaceuticals in the third quarter valued at about $19,473,000.

Mirum Pharmaceuticals Stock Up 2.0 %

NASDAQ:MIRM opened at $45.15 on Tuesday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The company has a market cap of $2.21 billion, a PE ratio of -22.35 and a beta of 1.04. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $54.23. The stock has a 50-day simple moving average of $47.51 and a 200 day simple moving average of $43.59.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. On average, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on MIRM shares. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. HC Wainwright raised their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $58.20.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the completion of the transaction, the senior vice president now directly owns 2,926 shares in the company, valued at $125,291.32. This trade represents a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Peter Radovich sold 1,998 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $85,554.36. Following the completion of the transaction, the chief operating officer now owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. This represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,915 shares of company stock worth $1,897,920. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.